TABLE 3. Summary of recommended intervals, by risk and age groups, for persons with indications to receive PCV13 and PPSV23 sequence Advisory Committee on Immunization — Practices, United States, September 2015 Intervals for Intervals for sequence, by age group sequence, by age group Risk 24–71 24–71 ≥65 ≥65 medical condition 18 64 ≥1 No underlying ≥1 NA NA NA NA NA NA chronic conditions year Immunocompetent persons Chronic disease Chronic lung disease ≥1 ≥8 ≥1 ≥8 Diabetes mellitus NA NA NA NA weeks year weeks Alcoholism* Chronic disease, cirrhosis* Cigarette smoking* Immunocompetent ≥8 ≥8 ≥1 ≥1 persons ≥8 ≥8 ≥8 ≥8 weeks Cerebrospinal leak
TABLE 3. Summary of recommended intervals, by risk and age groups, for persons with indications to receive PCV13 and PPSV23 sequence — Advisory Committee on Immunization Practices, United States, September 2015 Risk medical condition Intervals for sequence, by age group Intervals for sequence, by age group 24–71 ≥65 24–71 ≥65 No underlying chronic conditions NA NA NA ≥1 year NA NA NA ≥1 Immunocompetent persons Chronic disease Chronic lung disease Diabetes mellitus Alcoholism* Chronic disease, cirrhosis* Cigarette smoking* ≥8 weeks NA NA ≥1 year ≥8 weeks NA NA ≥1 Immunocompetent persons Cerebrospinal leak ≥8 weeks ≥8 ≥8 ≥8 ≥8 ≥8 ≥1 ≥1 64 18
2016CCSGPCV13ProtocolFINAL.docx